Sanofi’s Toujeo Is Approved, Now The Hard Part: Commercialization
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi’s next-generation long-acting insulin will compete against an entrenched rival, the company’s own Lantus – a challenging proposition for any drug marketer, especially in the increasingly cost-conscious diabetes sector.
You may also be interested in...
Sanofi, Long-Time Leader In Diabetes, Is Exiting Diabetes Research
The company's decision to exit diabetes research is not necessarily surprising given the development and commercial challenges in the therapeutic area, but it's not insignificant either.
Sanofi Board Forces CEO Chris Viehbacher to Resign Amid Lantus Woes
Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.
GSK Reveals Big Changes As 2015 Growth Prospects Fizzle
GlaxoSmithKline’s all important asthma drug, Advair, has taken a hit and the impact is bleeding out to the rest of the business. As GSK braces for a challenging 2015, the company announced a £1 billion cost savings program and plans to explore an IPO for its HIV subsidiary ViiV Healthcare.